VBI-2601
- Generic Name
- VBI-2601
Brii Bio's BRII-179 Shows Promise in Identifying Responders for HBV Functional Cure
• New data from Brii Bio's Phase 2 ENSURE study reveals that patients who responded to BRII-179 achieved a 55.6% HBsAg seroclearance rate, compared to just 10% in non-responders, supporting a novel patient enrichment strategy.
• Combination therapy of elebsiran with PEG-IFNα demonstrated significantly higher HBsAg loss rates (26.3-33.3%) compared to PEG-IFNα alone (5.6%) at 48 weeks in chronic HBV patients.
• The findings suggest BRII-179 could serve as a predictive tool to identify patients more likely to respond to curative therapies, potentially improving functional cure rates while reducing unnecessary treatment exposure.
Brii Bio Acquires Full Rights to BRII-179 and Completes Enrollment for ENRICH Study in HBV
• Brii Bio has acquired full intellectual property rights to BRII-179 from VBI Vaccines for $18 million, securing uninterrupted clinical supply and complete ownership.
• The acquisition supports Brii Bio's strategy to develop combination treatments for a functional cure for chronic Hepatitis B Virus (HBV) infection.
• The Phase 2b ENRICH study, evaluating sequential treatment of BRII-179 followed by elebsiran and PEG-IFNα combination, has completed patient enrollment.
• BRII-179 has received Breakthrough Therapy Designation from China's NMPA and is being investigated for its potential to identify HBV patients responsive to curative treatments.
Vir Biotechnology's Tobevibart and Elebsiran Combination Shows Promise in Chronic Hepatitis B Treatment
• A Phase 2 trial of tobevibart and elebsiran, with or without pegylated interferon alfa, shows promising HBsAg loss rates in chronic hepatitis B patients.
• In patients with low baseline HBsAg, 39% achieved HBsAg loss with tobevibart and elebsiran, while 46% achieved it with the triplet combination.
• The safety profile of the doublet regimen was consistent with prior studies, with mostly mild to moderate treatment-emergent adverse events.
• Key data regarding functional cure from the 24-week follow-up are expected in the second quarter of 2025, which will inform future clinical development.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath